Arthur F Ryan sold $78k of REGN
director at REGENERON PHARMACEUTICALS, INC.. 100 shares at an average of $777.27, traded Apr 1, 2026, filed Apr 3, 2026.
Score components
- +15RoleDirector
- +9Trade size$78k at market
- 0Share of holdings soldSold 0.6% of holdings
- 0ClusterNo other insider selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001104659-26-039613, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Apr 1, 2026 | SOpen-market sale Common Stock10b5-1 | -1 | $771.32 | $771 | 17,702 | Apr 3, 2026 |
| Apr 1, 2026 | SOpen-market sale Common Stock10b5-1 | -3 | $772.76 | $2,318 | 17,699 | Apr 3, 2026 |
| Apr 1, 2026 | SOpen-market sale Common Stock10b5-1 | -8 | $773.59 | $6,189 | 17,691 | Apr 3, 2026 |
| Apr 1, 2026 | SOpen-market sale Common Stock10b5-1 | -8 | $774.58 | $6,197 | 17,683 | Apr 3, 2026 |
| Apr 1, 2026 | SOpen-market sale Common Stock10b5-1 | -14 | $775.58 | $11k | 17,669 | Apr 3, 2026 |
| Apr 1, 2026 | SOpen-market sale Common Stock10b5-1 | -13 | $776.62 | $10k | 17,656 | Apr 3, 2026 |
| Apr 1, 2026 | SOpen-market sale Common Stock10b5-1 | -9 | $777.42 | $6,997 | 17,647 | Apr 3, 2026 |
| Apr 1, 2026 | SOpen-market sale Common Stock10b5-1 | -4 | $778.24 | $3,113 | 17,643 | Apr 3, 2026 |
| Apr 1, 2026 | SOpen-market sale Common Stock10b5-1 | -40 | $779.71 | $31k | 17,603 | Apr 3, 2026 |
Related signals
Other insiders at REGENERON PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 13Weak | REGENERON PHARMACEUTICALS, INC. | Kathryn Guarini director | $340k 400 shares | -40% | |
| 33Weak | REGENERON PHARMACEUTICALS, INC. | Marion McCourt EVP Commercial | $2.0M 2,346 shares | -16% | |
| 12Weak | REGENERON PHARMACEUTICALS, INC. | Kathryn Guarini director | $320k 400 shares | -40% | |
| 18Weak | REGENERON PHARMACEUTICALS, INC. | Huda Y Zoghbi director | $640k 800 shares | -32% | |
| 6Weak | REGENERON PHARMACEUTICALS, INC. | Arthur F Ryan director | $130k 200 shares | -1% | |
| 3Weak | REGENERON PHARMACEUTICALS, INC. | Arthur F Ryan director | $71k 100 shares | -1% | |
| 12Weak | REGENERON PHARMACEUTICALS, INC. | Arthur F Ryan director | $79k 100 shares | -1% | |
| 30Weak | REGENERON PHARMACEUTICALS, INC. | Huda Y Zoghbi director | $1.3M 1,638 shares | -49% | |
| 30Weak | REGENERON PHARMACEUTICALS, INC. | Jason Pitofsky SVP Controller | $1.6M 2,036 shares | -32% | |
| 19Weak | REGENERON PHARMACEUTICALS, INC. | Arthur F Ryan director | $78k 100 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.